NIMH plans funding for a research network to study the real-world effectiveness, safety, and implementation of rapid-acting psychotropic drugs for serious mental illnesses.
This grant has transitioned from forecasted to posted and is now accepting applications.
Funder: National Institutes of Health
Due Dates: June 10, 2027 (Application)
Funding Amounts: $12 million estimated total program funding; 3 expected awards; project periods up to 5 years
Summary: Supports coordinated clinical trial networks generating real-world evidence on safe, effective, and sustainable delivery of rapid-acting psychotropic interventional drugs.
Key Information: Only large-scale pragmatic clinical trial networks are supported; foreign organizations and foreign components are not allowed.
The National Institute of Mental Health (NIMH) and National Institute on Drug Abuse (NIDA) support the establishment of a Rapid-Acting Psychotropic Interventional Drugs–Clinical Trials Network (RAPIDs-CTN). The program seeks actionable evidence for routine clinical use of treatments that reduce symptoms within hours to days, focusing on serious mental illnesses, treatment-resistant psychiatric conditions, and urgent suicide risk.
Networks must combine a centralized Data Coordinating Center (DCC) with federated clinical sites conducting pragmatic trials in real-world care settings. Priorities include clinical effectiveness and safety, workforce and monitoring needs, retreatment frequency, healthcare costs, and sustainable delivery models. The milestone-driven UM1 cooperative agreement supports network establishment and pilot studies in Years 1–2, followed by full-scale pragmatic trials in Years 3–5. Networks should be able to adapt to newly approved treatments.